Summary
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
Description
THE PHARMACEUTICAL MARKET: GERMANY - REVIEW
Germany has one of the most advanced economies in the world. It is the fourth largest, behind the USA, China and Japan. According to the Economist Intelligence Unit (EIU), Germany's toughest challenge and largest risk to stability in the 2012-16 period will be the euro area debt crisis. Germany spends more on health than any other European country, but expenditure is not expected to grow rapidly over the next five years. The percentage of GDP spent on health is not expected to change greatly in the forecast period, although per capita spending will remain above average for the region, similar to that in France or Austria.
The German pharmaceutical market is twice the size of Italy; in per capita terms, it is similar to France. OTCs represent around 12% of the market and generics account for over a third. The market is predicted to increase at a low CAGR between 2011 and 2016. Growth in recent years has tended to be uneven, as government reforms take effect on pricing and/or reimbursement. A new law passed in November 2010 designed to bring down the average price of drugs is expected to dampen growth slightly over the next few years. The law reduces the power that pharmaceutical companies have in deciding what to charge for new prescription drugs. New, innovative drugs have been targeted as they were entirely responsible for the increase in drug spending in 2009. The German biologic market is expanding; biopharmaceuticals are expected to represent a fifth of the overall pharmaceutical market by 2020, according to Sandoz.
Reimbursement changes and greater use of substitution have placed a lot of pressure on older branded drugs, and prescribers and patients have been given financial incentives to switch to generics. However, reforms have not been especially 'pro-generic', so whilst generics will continue to be increasingly widely prescribed, their value share of the overall market will alter less rapidly. Generic drugs in Germany account for over a third of the prescription market by value. In volume terms, the generic market has continued to grow each year. In November 2011, Stada Arzneimittel signed a deal to acquire Spirig Pharma's generic business.
ENHANCED STRATEGIC INTELLIGENCE
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
